The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRCT | -47.64% | N/A | N/A | -17% |
| S&P | +16.9% | +95.99% | +14.39% | +52% |
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $79.18M | 48.4% |
| Gross Profit | $50.16M | 66.0% |
| Gross Margin | 63.35% | 6.7% |
| Market Cap | $3.19B | 1.4% |
| Market Cap / Employee | $4.22M | 0.0% |
| Employees | 756 | 20.8% |
| Net Income | -$19.58M | 23.6% |
| EBITDA | -$20.60M | 19.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $302.72M | 41.4% |
| Accounts Receivable | $80.82M | 37.2% |
| Inventory | 67 | 52.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $77.31M | -2.4% |
| Short Term Debt | $2.06M | 16.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.96% | 13.1% |
| Return On Invested Capital | -29.56% | 12.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.85M | -6.4% |
| Operating Free Cash Flow | -$15.04M | 4.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.32 | 17.41 | 7.93 | 8.18 | -31.19% |
| Price to Sales | 20.85 | 19.31 | 12.84 | 11.62 | -34.96% |
| Price to Tangible Book Value | 17.39 | 17.48 | 7.94 | 8.20 | -31.33% |
| Enterprise Value to EBITDA | -192.00 | -223.56 | -114.13 | -144.18 | 22.00% |
| Return on Equity | -37.0% | -26.8% | -27.6% | -26.4% | -48.12% |
| Total Debt | $80.64M | $80.25M | $79.81M | $79.37M | -2.04% |
PRCT earnings call for the period ending June 30, 2022.
PRCT earnings call for the period ending December 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
